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Introduction
In 2018, 1.276 men were assumed to be diagnosed with 
prostate cancer (PC) worldwide and around 6,800 in Swit-
zerland [1]. PC prognosis has substantially improved dur-
ing the past decades, leading to five-year relative survival 
rates of 90% to 95% in developed countries (Switzerland 
90%) [2-4]. Consequently, the number of men being alive 
five years after initial diagnosis of PC (long-term survivors 
[5]) has substantially increased [6]. For Switzerland it was 
projected that in 2015 around 32,818 men will be PC 
long-term survivors. This number has tripled since 2000 
[7]. As the number of long-term PC survivors continues 
to increase, it is important to assess and understand cancer 
survivorship aspects, such as health-related quality of life 
(HRQoL) and symptom burden [8, 9]. 
So far, studies assessing HRQoL in long-term PC survi-
vors, reported that long-term PC survivors have generally 
good HRQoL, which is relatively comparable to that of 
population controls [10]. However, PC survivors do expe-
rience detriments in specific aspects of HRQoL (e.g. so-
cial, role, emotional and physical function), higher symp-
tom burden for example in fatigue, diarrhoea, erectile 
dysfunction and urinary problems as well as higher de-
pression and anxiety rates [11-13]. Moreover, HRQoL and 
well-being are influenced by several factors such as clinical 
and demographic characteristics [14]. Treatment can also 
represent a crucial factor in explaining HRQoL differences 
among cancer patients [11, 13]. Therefore, information on 
HRQoL has the potential to support treatment decision-
making and post-treatment health care for survivors and 
health care providers [15, 16].
So far, research regarding HRQoL, symptoms and psycho-
logical well-being in long-term PC survivors is relying on 
data mostly from the US and to a small extent from Scan-
dinavian countries, the Netherlands, the UK and Germa-
ny [11, 13, 17]. Differences in health care administration 
including follow-up of PC survivors and rehabilitation 
may limit the generalizability of the current knowledge 
regarding HRQoL, symptoms and psychological well-
being in long-term PC survivors. The Prostate Cancer 
Survivorship in Switzerland (PROCAS) project aimed 
at filling the gap in existing knowledge about HRQoL, 
symptoms as well as disease and treatment-related late ef-
fects of long-term PC survivors in Switzerland.
Study Objectives
The overall aim of the PROCAS study was to provide 
knowledge on HRQoL, symptoms as well as disease and 
treatment-related late effects in long-term PC survivors 
for patients, health care professionals and caregivers.
In detail, we defined as our primary objective to describe 
HRQoL in long-term PC survivors in Switzerland de-
pending on personal and medical factors, such as: age, 
tumour stage, language group, treatment, socioeconomic 
status and comorbidities. In our secondary objective we 
aimed to identify determinants for negative and positive 
effects on HRQoL.
Study Design and Inclusion Criteria 
PROCAS is a multiregional cohort study with prospective 
collection of information about HRQoL, symptoms, psy-
chological well-being, personal and medical data of long-
term PC survivors. The study was developed in close co-
operation with involved Swiss cancer registries, the Swiss 
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Fig. 1. PROCAS Study Regions. 
RFT - Registre Fribourgeois des 
Tumeurs, KRBB - Krebsresgister 
beider Basel, KSGR - Krebsregister 
Graubünden und Glarus, KROCH 
Krebsregister Ostschweiz, RVST - 
Registre Valaisan des Tumeurs & 
KRZHZG - Krebsregister der Kantone 
Zürich und Zug.
tres drew random subsamples of patients who had been re-
ferred by the participating urologists from their registries 
or from patients who participated in the Patterns of Care 
study [18]. 1,246 participants were then invited to par-
ticipate in the study by their referring urologist by postal 
mail (Fig. 2). Out of these, 1,194 could finally be contact-
ed and received an invitation letter, the patient question-
naires (A) and informed consent by postal mail between 
February 2017 and March 2018. Totally, 748 participants 
NICER
Society of Urology and the Swiss Patient Organisation for 
Urological Diseases. The National Institute of Cancer Epi-
demiology and Registration (NICER) was the central study 
centre for this study. Six cancer registries (Registre Fri-
bourgeois des Tumeurs (RFT), Krebsresgister beider Basel 
(KRBB), Krebsregister Graubünden und Glarus (KSGR), 
Krebsregister Ostschweiz (KROCH), Registre Valaisan des 
Tumeur (RVST) & Krebsregister der Kantone Zürich und 
Zug (KRZHZG)) were involved as regional study centres 
(Fig. 1). This selection was a result of an open call to all ten 
cancer registries that were established prior to 2006. 
Totally, 8,712 PC survivors fulfilled the inclusion criteria, 
which were: 
• Male subjects
• Diagnosed with prostate cancer (ICD-10 C61) between 
1th January 2006 and 31th December 2011 
• Registered by one of the following cancer registries: 
RFT, KRBB, KSGR, KROCH, RVST & KRZHZG
• Age at diagnosis between 25 and 75 years
• Alive at time of enrolment
• Able to complete the questionnaire (assistance is pos-
sible) 
• Able to understand German, French or Italian
• No concurrent bladder cancer
Data Collection and Measurements
In a first step, all urological hospital clinics and estab-
lished urologists in the participating cantons were invited 
to participate in the study. Secondly, regional study cen- Fig. 2. Recruitment of Prostate Cancer Survivors.
• Unknown to doctor; 
N=23
• Deceased; N=9
• Lost to follow-up; N=8
• Not invited by doctor for 
medical reasons; N=3
• Initially treated or 
followed by other 
physician or by other 
clinic; N=59
Non-respondents; N=446
Total sampling Frame;
N=8,712
Eligible patients of consenting doctor, 
selected from registries' data bases, 
before vital status check by register;
N=1,348
Patients invited by doctor; N=1,246
Final study participants: Invited by
doctor, meeting inclusion criteria, valid
postal address; N=1,194
Respondents; N=748
• Reported as deceased 
by next of kin; N=32
• Reported as not able to 
fill in questionnaire by 
next of kin; N=10 
• No valid postal address; 
N=10
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responded (Response Rate: 62.6%) and sent back the doc-
uments. Non-responders received one reminder. In case 
of questions, participants could phone the central study 
center. After receiving the documents from the patients, 
regional study centres asked the referring physician to 
provide additional medical data via a short physicians’ 
questionnaire (B). All documents were available in Ger-
man, French and Italian.
After the recruitment of patients for this project, re-
gional study centres prepared a coded patient data extract 
(C) of all patients fulfilling the inclusion criteria for the 
 PROCAS project. The data extract included status of par-
ticipation (respondents, non-respondents & not-invited) 
and clinical information.
Clinical Data
Data regarding initial tumour stage, year of birth and year 
of initial diagnosis was obtained from the data extract (C) 
from the participating cancer registry.
More detailed information on treatment, relapse/disease 
progression and other primary tumours were gathered via 
the physicians’ questionnaire (B). Participating survivors 
were also asked information in the patient questionnaire 
(A) about their treatment, recurrence/disease progression 
and other primary tumours to supplement the informa-
tion from the urologists and cancer registries. Moreover, 
participants gave information about their comorbidities. 
Sociodemographic Data
Information on age, nationality, marital status, education, 
occupation and Body-Mass-Index were provided by the 
patients (A).
HRQoL, Symptoms and Psychological Well-being Data
All instruments used in the patient questionnaire (A) to 
assess HRQoL, symptoms and psychological well-being 
have sound psychometric properties and are validated in 
German, French and Italian. This allows us to compare 
our results with results from other studies.
The following questionnaires were used:
• HRQoL was assed using the EORTC QLQ-C30 ques-
tionnaire [19].
• PC-specific symptom burden was assessed using the 
EORTC QLQ-PR25 questionnaire and specific items 
of the EPIC-26 [20,21].
• Fatigue was assessed using the EORTC QLQ-FA12 
[22].
• The Mental Health Inventory (MHI) -5 was used to 
asses mental health [23].
• To measure spiritual well-being the FACIT-sp ques-
tionnaire was used [24].
Ethical Aspects
The study has been approved as a multi-centre study by 
the Ethics Committee Zurich and by all review boards ac-
countable for the participating cancer registries (BASEC 
Number: 2016-00608). All participants were asked to 
provide written informed consent. 
Results
The mean age of respondents at data collection was 73.2 
years and mean time since diagnosis was 7.6 years (range: 
5-10 years) (Tab. 1). Most study participants were of 
Swiss nationality and were living with their partner. Non-
respondents and eligible PC survivors, who had not been 
invited, were significantly older, were less likely to be 
Swiss and to live together with their partners. There were 
no significant differences regarding disease extension.
The most common school degree among participants was 
a secondary school degree (43.1%) and most participants 
were retired (85.7%). In total, 22.3% had experienced 
disease progression and/or relapse and 6.6% reported a 
second primary cancer. The most common primary thera-
py was radical prostatectomy (67.0%), followed by exter-
nal-beam radiation therapy (21.5%) and hormonotherapy 
(16.6%). Finally, the most common self-reported comor-
bidities were arthritis/rheumatism/arthroses (23.4%), 
visual impairment (17.9%), degenerative disc disease 
(17.5%) and hearing loss (14.4%).
Discussion
This is the first study in Switzerland in which population-
based cantonal cancer registries contributed to the recruit-
ment of cancer survivors, in this case long-term PC survi-
vors. Therefore, the PROCAS study will allow us to assess 
HRQoL, well-being and symptom burden from a repre-
sentative sample of long-term PC survivors. Through the 
multiregional approach, including patient recruitment 
via six population-based cancer registries located in the 
German and French speaking region, PROCAS represents 
a sociodemographically diverse cohort with patients not 
exclusively treated at large hospitals. Moreover, the good 
sample size together with the variety of validated instru-
ments and clinical and sociodemographic data, will allow 
us to perform a variety of analyses to get an in-depth un-
derstanding of HRQoL, well-being and symptom burden 
of long-term PC survivors. Finally, the PROCAS study 
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Respondents 
Col%
Non-Respondents 
Col%
Not-Invited 
Col%
Respondents vs. 
Non-Respondents
p-value
Respondents vs. 
Not-Invited
p-value
C
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Total (N)
Age at survey
<70 years
70-74 years
75-79 years
>79 years
Mean (SD)
Time since diagnosis
5-6
7-8
9-10
Mean (SD)
Nationality
Swiss
Non-Swiss
Unknown
Living with partner 
Yes
No
Unknown
Extension of disease
Local
Regional
Distant
Unknown
Cancer Stage
I
II
III
IV
Unknown
(748)
25.8
13.6
25.1
17.5
73.2 (6.4)
27.3
42.0
30.7
7.6 (1.5)
90.4
4.5
5.1
71.1
18.9
10.0
 
78.6
15.1
5.2
1.1
13.9
56.6
17.0
6.0
6.6
(446)
22.9
25.8
32.3
19.1
74.0 (6.2)
25.8
41.3
32.9
7.7 (1.5)
81.6
12.3
6.1
62.7
19.5
17.8
76.7
16.4
4.0
2.9
21.5
46.6
17.7
5.2
9.0
(7,518)
22.6
27.0
28.7
21.5
74.0 (6.4)
31.9
36.7
31.4
8.0 (1.6)
81.2
9.1
9.7
65.5
16.0
18.5
76.7
13.0
3.8
6.5
18.5
46.1
14.4
4.7
16.3
0.035
0.035
0.32
0.32
0.001
0.007
0.410
0.34
<0.001
0.002
0.053
0.053
0.001
0.003
0.074
0.045
Q
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re
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a
Education (highest degree)1
Primary school or no degree
Secondary
Tertiary
Unknown
Employment at survey
Full-time
Part-time
(Early) Retirement
Invalidity Insurance
Other
Unknown
Disease progression/relapse (yes)
Unknown
Second primary cancer after PC (yes)
Unknown
Comorbidities (self-report)
Arthritis/Rheumatism/Arthroses
Visual Impairment
Degenerative Disc Disease
Hearing Loss
Primary Therapy
Radical Prostatectomy
External Beam Radiation Therapy
Brachytherapy
Androgen Deprivation Therapy
Watchful Waiting/Active Surveillance
1.5
53.1
44.4
1.1
7.6
2.8
85.7
2.7
0.9
0.3
22.3
1.2
6.6
0.5
23.4
17.9
17.5
14.4
67.0
21.5
4.6
16.6
6.4
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
Tab. 1. Demographic and clinical characteristics of respondents, non-respondents and not-invited PC survivors.
1. Education: Low (no or primary school); Medium (lower general secondary education or vocational training); High (pre-university education, high vocational training, university).
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supplements data of HRQoL, well-being and symptom 
burden of the large group of PC survivors who are living 
in Switzerland and are still alive. 
However, some limitations have to be considered when 
analysing the data. Despite the good response rate of 
62.6%, there is a possibility of healthy survivor bias. Ad-
ditionally, due to lack of baseline HRQoL data, we can-
not adjust for baseline HRQoL. Moreover, even though 
we have a range of demographic and clinical data, we do 
not have all information on factors related to treatment 
(e.g. on digital rectal exam results, PSA-values, Gleason 
scores). Additionally, for data protection reasons, direct 
contact to patients via cancer registries is not possible, 
leading to a selection bias as not all urologists were will-
ing to participate in the study.
Nevertheless, the study will assist researchers, survivors, 
caregivers and health care professionals in understanding 
the potential impact of PC treatments on HRQoL as well 
as get information on the symptom burden patterns in 
long-term survivors by treatment, stage, age and/or social 
demographic factors.
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Neue Therapieoptionen – neue Herausforderungen
Veränderungen an Haut, Schleimhaut, Nägeln und 
Haaren unter medikamentöser Tumortherapie, sowie 
in Kombination mit Radiotherapie, sind zunehmend, 
klinisch relevant und fordern einen multidisziplinären 
Managementansatz. Pflegefachpersonen im Bereich 
Onkologie nehmen hierbei eine Schlüsselrolle ein.
Damit Onkologiepflegefachpersonen im Management 
dermatologischer Reaktionen wirksam sowie indi-
viduell agieren, unterstützen und begleiten können, 
werden aktuelle fachliche Kenntnisse und spezifische 
Kompetenzen benötigt.
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